BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poulter JA, Collins JC, Cargo C, De Tute RM, Evans P, Ospina Cardona D, Bowen DT, Cunnington JR, Baguley E, Quinn M, Green M, McGonagle D, Beck DB, Werner A, Savic S. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 2021;137:3676-81. [PMID: 33690815 DOI: 10.1182/blood.2020010286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Ronsin C, Benard L, Mourtada A, Perrin F, Boukerroucha Z. Acute tubulointerstitial nephritis revealing VEXAS syndrome. Kidney Int 2022;101:1295-7. [PMID: 35597594 DOI: 10.1016/j.kint.2022.03.012] [Reference Citation Analysis]
2 Oganesyan A, Hakobyan Y, Terrier B, Georgin-Lavialle S, Mekinian A. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome. Semin Hematol 2021;58:247-53. [PMID: 34802547 DOI: 10.1053/j.seminhematol.2021.10.003] [Reference Citation Analysis]
3 Lacombe V, Prevost M, Bouvier A, Thépot S, Chabrun F, Kosmider O, Lacout C, Beucher A, Lavigne C, Geneviève F, Urbanski G. Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold. Br J Haematol 2021. [PMID: 34340250 DOI: 10.1111/bjh.17679] [Reference Citation Analysis]
4 Takahashi N, Takeichi T, Nishida T, Sato J, Takahashi Y, Yamamura M, Ogi T, Akiyama M. Clinical Images: Extensive multiple organ involvement in VEXAS syndrome. Arthritis Rheumatol 2021. [PMID: 33881233 DOI: 10.1002/art.41775] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Poulter JA, Savic S. Genetics of somatic auto-inflammatory disorders. Semin Hematol 2021;58:212-7. [PMID: 34802542 DOI: 10.1053/j.seminhematol.2021.10.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Patel N, Dulau-Florea A, Calvo KR. Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome. Semin Hematol 2021;58:204-11. [PMID: 34802541 DOI: 10.1053/j.seminhematol.2021.10.007] [Reference Citation Analysis]
7 Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y, Taguri M, Yamanaka S, Takase-Minegishi K, Yoshimi R, Fujii S, Nakajima H, Matsumoto N. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis 2021:annrheumdis-2021-220089. [PMID: 33789873 DOI: 10.1136/annrheumdis-2021-220089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Pàmies A, Ferràs P, Bellaubí-Pallarés N, Giménez T, Raventós A, Colobran R. VEXAS syndrome: relapsing polychondritis and myelodysplastic syndrome with associated immunoglobulin A vasculitis. Rheumatology (Oxford) 2021:keab782. [PMID: 34668539 DOI: 10.1093/rheumatology/keab782] [Reference Citation Analysis]
9 van der Made CI, Potjewijd J, Hoogstins A, Willems HPJ, Kwakernaak AJ, de Sevaux RGL, van Daele PLA, Simons A, Heijstek M, Beck DB, Netea MG, van Paassen P, Elizabeth Hak A, van der Veken LT, van Gijn ME, Hoischen A, van de Veerdonk FL, Leavis HL, Rutgers A. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS. J Allergy Clin Immunol 2021:S0091-6749(21)00819-8. [PMID: 34048852 DOI: 10.1016/j.jaci.2021.05.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Mitrovic S, Fautrel B. Clinical Phenotypes of Adult-Onset Still's Disease: New Insights from Pathophysiology and Literature Findings. J Clin Med 2021;10:2633. [PMID: 34203779 DOI: 10.3390/jcm10122633] [Reference Citation Analysis]
11 Heiblig M, Patel BA, Groarke EM, Bourbon E, Sujobert P. Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol 2021;58:239-46. [PMID: 34802546 DOI: 10.1053/j.seminhematol.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lacombe V, Beucher A, Urbanski G, Le Corre Y, Cottin L, Croué A, Bouvier A. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 2022;11:6. [PMID: 35172893 DOI: 10.1186/s40164-022-00262-5] [Reference Citation Analysis]
13 Savic S, Coe J, Laws P. Autoinflammation: Interferonopathies and Other Autoinflammatory Diseases. J Invest Dermatol 2021:S0022-202X(21)02406-4. [PMID: 34887082 DOI: 10.1016/j.jid.2021.07.189] [Reference Citation Analysis]
14 Bert-Marcaz C, Briantais A, Faucher B, Corazza G, Ebbo M, Attarian S, Delmont E, Fortanier E. Expanding the spectrum of VEXAS syndrome: association with acute-onset CIDP. J Neurol Neurosurg Psychiatry 2021:jnnp-2021-327949. [PMID: 34872982 DOI: 10.1136/jnnp-2021-327949] [Reference Citation Analysis]
15 Shaukat F, Hart M, Burns T, Bansal P. UBA1 and DNMT3A Mutations in VEXAS Syndrome. A Case Report and Literature Review. Mod Rheumatol Case Rep 2021:rxab021. [PMID: 34480172 DOI: 10.1093/mrcr/rxab021] [Reference Citation Analysis]
16 Koster MJ, Kourelis T, Reichard KK, Kermani TA, Beck DB, Cardona DO, Samec MJ, Mangaonkar AA, Begna KH, Hook CC, Oliveira JL, Nasr SH, Tiong BK, Patnaik MM, Burke MM, Michet CJ Jr, Warrington KJ. Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. Mayo Clin Proc 2021;96:2653-9. [PMID: 34489099 DOI: 10.1016/j.mayocp.2021.06.006] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Oo TM, Koay JTJ, Lee SF, Lee SMS, Lim XR, Fan BE. Thrombosis in VEXAS syndrome. J Thromb Thrombolysis 2021. [PMID: 34817788 DOI: 10.1007/s11239-021-02608-y] [Reference Citation Analysis]
18 Grey A, Cheong PL, Lee FJ, Abadir E, Favaloro J, Yang S, Adelstein S. A Case of VEXAS Syndrome Complicated by Hemophagocytic Lymphohistiocytosis. J Clin Immunol 2021. [PMID: 34080084 DOI: 10.1007/s10875-021-01070-y] [Reference Citation Analysis]
19 Comont T, Heiblig M, Rivière E, Terriou L, Rossignol J, Bouscary D, Rieu V, Le Guenno G, Mathian A, Aouba A, Vinit J, Dion J, Kosmider O, Terrier B, Georgin-Lavialle S, Fenaux P, Mekinian A; French VEXAS study group, Groupe Francophone des Myélodysplasies (GFM) and MedecineINterne, HEmato et ONco (MINHEMON) group. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol 2021. [PMID: 34651299 DOI: 10.1111/bjh.17893] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Comont T, Treiner E, Vergez F. From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review. Diagnostics (Basel) 2021;11:1982. [PMID: 34829329 DOI: 10.3390/diagnostics11111982] [Reference Citation Analysis]
21 Groarke EM, Dulau-Florea AE, Kanthi Y. Thrombotic manifestations of VEXAS syndrome. Semin Hematol 2021;58:230-8. [PMID: 34802545 DOI: 10.1053/j.seminhematol.2021.10.006] [Reference Citation Analysis]
22 Beck DB, Werner A, Kastner DL, Aksentijevich I. Disorders of ubiquitylation: unchained inflammation. Nat Rev Rheumatol 2022. [PMID: 35523963 DOI: 10.1038/s41584-022-00778-4] [Reference Citation Analysis]
23 Matsumoto H, Asano T, Tsuchida N, Maeda A, Yoshida S, Yokose K, Fujita Y, Temmoku J, Matsuoka N, Yashiro-furuya M, Sato S, Irie K, Norikawa N, Yamamoto T, Endo M, Fukuchi K, Ohkawara H, Ikezoe T, Uchiyama Y, Kirino Y, Matsumoto N, Watanabe H, Migita K. Behçet's disease with a somatic UBA1 variant: Expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.108996] [Reference Citation Analysis]
24 Koster MJ, Warrington KJ. VEXAS within the spectrum of rheumatologic disease. Semin Hematol 2021;58:218-25. [PMID: 34802543 DOI: 10.1053/j.seminhematol.2021.10.002] [Reference Citation Analysis]
25 Kusne Y, Fernandez J, Patnaik MM. Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones? Semin Hematol 2021;58:226-9. [PMID: 34802544 DOI: 10.1053/j.seminhematol.2021.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sikora KA, Wells K, Bolek EC, Jones AI, Grayson PC. Somatic Mutations in Rheumatologic Diseases: VEXAS Syndrome and Beyond. Rheumatology (Oxford) 2021:keab868. [PMID: 34888629 DOI: 10.1093/rheumatology/keab868] [Reference Citation Analysis]
27 Goetzke CC, Ebstein F, Kallinich T. Role of Proteasomes in Inflammation. J Clin Med 2021;10:1783. [PMID: 33923887 DOI: 10.3390/jcm10081783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK, Ferrada MA, Wu Z, Gutierrez-Rodrigues F, Lotter J, Wilson L, Hoffmann P, Cardona DO, Patel N, Dulau-Florea A, Kastner DL, Grayson PC, Beck DB, Young NS, Calvo KR. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 2021;5:3203-15. [PMID: 34427584 DOI: 10.1182/bloodadvances.2021004976] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
29 Patel BA, Ferrada MA, Grayson PC, Beck DB. VEXAS syndrome: An inflammatory and hematologic disease. Semin Hematol 2021;58:201-3. [PMID: 34802540 DOI: 10.1053/j.seminhematol.2021.10.005] [Reference Citation Analysis]